DE69725739D1 - Meningokokkus b-epitop ausbildende monoklonale antikoerper und deren verwendung zur herstellung von impfstoffzusammenstellungen - Google Patents

Meningokokkus b-epitop ausbildende monoklonale antikoerper und deren verwendung zur herstellung von impfstoffzusammenstellungen

Info

Publication number
DE69725739D1
DE69725739D1 DE69725739T DE69725739T DE69725739D1 DE 69725739 D1 DE69725739 D1 DE 69725739D1 DE 69725739 T DE69725739 T DE 69725739T DE 69725739 T DE69725739 T DE 69725739T DE 69725739 D1 DE69725739 D1 DE 69725739D1
Authority
DE
Germany
Prior art keywords
menb
vaccine compositions
mimetics
antibodies
epitop
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69725739T
Other languages
English (en)
Other versions
DE69725739T2 (de
Inventor
Dan Granoff
R Moe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Childrens Hospital Oakland Research Center
Original Assignee
Cincinnati Childrens Hospital Medical Center
Childrens Hospital Oakland Research Center
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cincinnati Childrens Hospital Medical Center, Childrens Hospital Oakland Research Center , Chiron Corp filed Critical Cincinnati Childrens Hospital Medical Center
Application granted granted Critical
Publication of DE69725739D1 publication Critical patent/DE69725739D1/de
Publication of DE69725739T2 publication Critical patent/DE69725739T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/22—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Neisseriaceae (F), e.g. Acinetobacter
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/807—Hapten conjugated with peptide or protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69725739T 1996-08-27 1997-08-27 Meningokokkus b-epitop ausbildende monoklonale antikoerper und deren verwendung zur herstellung von impfstoffzusammenstellungen Expired - Lifetime DE69725739T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2579996P 1996-08-27 1996-08-27
US25799 1996-08-27
PCT/US1997/015167 WO1998008874A1 (en) 1996-08-27 1997-08-27 Monoclonal antibodies that define unique meningococcal b epitopes and their use in the preparation of vaccine compositions

Publications (2)

Publication Number Publication Date
DE69725739D1 true DE69725739D1 (de) 2003-12-11
DE69725739T2 DE69725739T2 (de) 2004-08-05

Family

ID=21828119

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69725739T Expired - Lifetime DE69725739T2 (de) 1996-08-27 1997-08-27 Meningokokkus b-epitop ausbildende monoklonale antikoerper und deren verwendung zur herstellung von impfstoffzusammenstellungen

Country Status (7)

Country Link
US (4) US6048527A (de)
EP (1) EP0922059B1 (de)
JP (2) JP4150082B2 (de)
AT (1) ATE252602T1 (de)
CA (1) CA2264585C (de)
DE (1) DE69725739T2 (de)
WO (1) WO1998008874A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9422096D0 (en) * 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
US5811102A (en) * 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
ATE208629T1 (de) * 1996-08-27 2001-11-15 Chiron Corp Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung
ATE252602T1 (de) * 1996-08-27 2003-11-15 Chiron Corp Meningokokkus b-epitop ausbildende monoklonale antikoerper und deren verwendung zur herstellung von impfstoffzusammenstellungen
PT1630168E (pt) 1997-08-27 2011-07-20 Novartis Vaccines & Diagnostic Compostos miméticos moleculares de péptidos de meningococos do serogrupo b
GB9823835D0 (en) * 1998-10-30 1998-12-23 Univ London Component for vaccine
JP2002536295A (ja) * 1998-12-14 2002-10-29 パラチン テクノロジーズ， インク． 金属ペプチド組合せライブラリ及びその利用法
ES2184659T1 (es) 1999-08-06 2003-04-16 Ivigene Corp Polinucleotidos microbianos expresados durante la infeccion de un organismo hospedante.
US7033748B2 (en) * 1999-08-06 2006-04-25 Ivigene Corporation Identification of microbial polynucleotides expressed during infection of a host
US7049398B1 (en) * 1999-08-12 2006-05-23 Palatin Technologies, Inc. Melanocortin metallopeptide constructs, combinatorial libraries and applications
US6838553B1 (en) * 1999-10-05 2005-01-04 Academia Sinica Peptide repeat immunogens
US7189405B1 (en) * 1999-10-29 2007-03-13 Rice Peter A Peptide mimics of conserved gonococcal epitopes and methods and compositions using them
WO2001036006A1 (en) * 1999-11-19 2001-05-25 Palatin Technologies, Inc. Opioid metallopeptide compositions and methods
DK2289545T3 (en) * 2000-01-17 2016-09-05 Glaxosmithkline Biologicals Sa Supplemented OMV vaccine against meningococcus
GB0024200D0 (en) * 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
US7385025B2 (en) * 2000-12-19 2008-06-10 Palatin Technologies, Inc. Metallopeptide compounds
AU2002238106A1 (en) * 2001-02-13 2002-08-28 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
US20020131953A1 (en) * 2001-03-14 2002-09-19 Ut Southwestern Medical Center In situ langerhans cell vaccine
RU2322451C2 (ru) * 2001-04-17 2008-04-20 Новартис Вэксинс Энд Диагностикс, Инк. Молекулярные миметики эпитопов менингококка в, которые вызывают выработку функционально активных антител
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
KR100506118B1 (ko) * 2002-04-19 2005-08-04 학교법인연세대학교 수막염균증 백신 조성물
EP1411061A1 (de) * 2002-10-16 2004-04-21 Centre National De La Recherche Scientifique (Cnrs) Poly-alpha2,8-sialylsäure mimetische Peptide und ihre Verwendungen
US20070020293A1 (en) * 2003-06-23 2007-01-25 Michon Francis J Vaccines against group neisseria meningitidis and meningococcal combinations thereof
AU2005244081B2 (en) * 2004-05-11 2011-10-06 Abgenomics Cooperatief U.A. T-cell death-inducing epitopes
US8148335B2 (en) * 2004-06-23 2012-04-03 Children's Hospital & Research Center Oakland De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
WO2006002402A2 (en) * 2004-06-23 2006-01-05 Children's Hospital & Research Center At Oakland Polysaccharide derivatives and uses in induction of an immune response
US8052971B2 (en) * 2005-11-21 2011-11-08 MG Biologics Oral use of specific antibodies for intestinal health
WO2007070372A2 (en) * 2005-12-09 2007-06-21 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation
MX2008008185A (es) * 2005-12-23 2008-11-14 Childrens Hosp & Res Ct Oak Antigenos de acido des-n-acetil-sialico, anticuerpos para los mismos, y metodos de uso en la terapia de cancer.
AR058736A1 (es) * 2005-12-29 2008-02-20 Ct Ingenieria Genetica Biotech Peptidos mimeticos de carbohidratos y su empleo en formulaciones farmaceuticas
CA2636983A1 (en) * 2006-01-13 2007-07-26 Baxter International Inc. Method for purifying polysaccharides
GB0606155D0 (en) * 2006-03-28 2006-05-10 Liverpool School Of Tropical M Bacterial vaccine
EP2007427A4 (de) * 2006-04-11 2012-04-04 Yeda Res & Dev Verbesserte impfstoffe mit multimeren hsp60-peptid-trägern
GB0611914D0 (en) * 2006-06-15 2006-07-26 Teti Giuseppe Peptides that mimic non-human cross-reactive protective epitopes of the group Bmeningococcal capsulsar polysaccharide
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
US20100189740A1 (en) * 2007-06-20 2010-07-29 Francis Michon Modified polysaccharides for conjugate vaccines
EP2183261A4 (de) * 2007-07-03 2010-09-15 Childrens Hosp & Res Ct Oak Polysialylsäurederivate, herstellungsverfahren und anwendungen bei der steigerung von produktion und targeting von krebsantigenen
CA2692419C (en) * 2007-07-03 2017-12-05 Children's Hospital & Research Center At Oakland Inhibitors of polysialic acid de-n-acetylase and methods for using the same
JP5702600B2 (ja) * 2007-07-03 2015-04-15 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド オリゴシアル酸誘導体、製造方法および免疫学的使用
US8067730B2 (en) 2007-07-20 2011-11-29 The George Washington University Laser ablation electrospray ionization (LAESI) for atmospheric pressure, In vivo, and imaging mass spectrometry
US20100285446A1 (en) * 2007-07-20 2010-11-11 Akos Vertes Methods for Detecting Metabolic States by Laser Ablation Electrospray Ionization Mass Spectrometry
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20090156459A1 (en) * 2007-11-16 2009-06-18 Pharmain Corporation Cationic-Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
WO2009117409A2 (en) * 2008-03-18 2009-09-24 Merck & Co., Inc. A high throughput protein interaction assay
TW201103980A (en) * 2009-07-08 2011-02-01 Abbott Biologicals Bv Viral vaccine and use thereof
KR101594228B1 (ko) 2010-08-23 2016-02-15 와이어쓰 엘엘씨 네이세리아 메닌기티디스 ｒＬＰ２０８６ 항원의 안정한 제제
AU2011300409B2 (en) 2010-09-10 2015-03-26 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
WO2012054879A1 (en) * 2010-10-22 2012-04-26 Duke University Compositions and methods for the treatment of septic arthritis, osteomyelitis, and bacteremia
WO2013085572A2 (en) 2011-07-14 2013-06-13 The George Washington University Plume collimation for laser ablation electrospray ionization mass spectrometry
US10598666B2 (en) * 2012-03-08 2020-03-24 Glaxosmithkline Biologicals Sa In vitro potency assay for protein-based meningococcal vaccines
KR101763625B1 (ko) 2012-03-09 2017-08-01 화이자 인코포레이티드 수막염균 조성물 및 이의 사용 방법
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
US9770504B2 (en) * 2013-05-03 2017-09-26 The Board Of Regents Of The University Of Texas System Generating peptoid vaccines
US9822150B2 (en) 2013-09-08 2017-11-21 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
KR20170103009A (ko) 2015-02-19 2017-09-12 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
EP0145359B1 (de) * 1983-11-21 1991-01-16 The Wellcome Foundation Limited Komplexe, Verfahren zu ihrer Herstellung und dieselben enthaltende Formulierungen
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
US4970070A (en) * 1986-02-07 1990-11-13 Genetic Systems Corporation Protective monoclonal antibody compositions for infections due to group B streptococcus
WO1990006696A2 (en) * 1988-12-19 1990-06-28 Praxis Biologics, Inc. Meningococcal class 1 outer-membrane protein vaccine
SU1708846A1 (ru) * 1989-11-22 1992-01-30 Научно-исследовательский институт вакцин и сывороток им.И.И.Мечникова Штамм бактерий NeISSeRIa меNINGIтIDIS серогруппы В - продуцент капсульного полисахарида и полисахаридно-белкового комплекса
AU641715B2 (en) * 1989-12-14 1993-09-30 National Research Council Of Canada Improved meningococcal polysaccharide conjugate vaccine
GB9422096D0 (en) * 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
US5811102A (en) 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
ATE252602T1 (de) 1996-08-27 2003-11-15 Chiron Corp Meningokokkus b-epitop ausbildende monoklonale antikoerper und deren verwendung zur herstellung von impfstoffzusammenstellungen
ATE208629T1 (de) * 1996-08-27 2001-11-15 Chiron Corp Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung
PT1630168E (pt) 1997-08-27 2011-07-20 Novartis Vaccines & Diagnostic Compostos miméticos moleculares de péptidos de meningococos do serogrupo b

Also Published As

Publication number Publication date
JP2001500372A (ja) 2001-01-16
US20040077840A1 (en) 2004-04-22
JP2008044947A (ja) 2008-02-28
DE69725739T2 (de) 2004-08-05
US7063949B2 (en) 2006-06-20
CA2264585A1 (en) 1998-03-05
EP0922059B1 (de) 2003-10-22
WO1998008874A1 (en) 1998-03-05
CA2264585C (en) 2005-06-14
US20060035284A1 (en) 2006-02-16
ATE252602T1 (de) 2003-11-15
US20020197260A1 (en) 2002-12-26
JP4150082B2 (ja) 2008-09-17
US7504254B2 (en) 2009-03-17
US6048527A (en) 2000-04-11
EP0922059A1 (de) 1999-06-16
US6642354B2 (en) 2003-11-04

Similar Documents

Publication Publication Date Title
DE69725739D1 (de) Meningokokkus b-epitop ausbildende monoklonale antikoerper und deren verwendung zur herstellung von impfstoffzusammenstellungen
Shoenfeld et al. Mycobacteria and autoimmunity
DE69840508D1 (de) Molekular-mimetika von meningokokkus b epitopen
NO912369L (no) Meningokokk-klasse-1-ytre-membranproteinvaksine.
BR9814276A (pt) Antìgenos de superfìcie
EP2270046A3 (de) Verfahren und Zusammensetzungen zur Behandlung von mit Hämolyse assoziierten Krankheiten
ATE240395T1 (de) Antikörper gegen e-selektin
LU92488I2 (fr) Dimethyl fumarate
BR0010721A (pt) Composições de neisserias combinadas
NO942750D0 (no) Monomere og dimere fusjonsproteiner av antistoff-fragment
BR9711457A (pt) Compostos e processo para o tratamento e diagnóstico de infecções micobacterianas.
RU2003133300A (ru) Молекулярные миметики эпитопов менингококка в, которые вызывают выработку функционально активных антител
DE59507920D1 (de) NEUE hIL-4-MUTANTENPROTEINE ALS ANTAGONISTEN ODER PARTIELLE AGONISTEN DES HUMANEN INTERLEUKIN 4
ATE281521T1 (de) Von filaggrin abgeleitete antigene und deren anwendung in der diagnose von rheumatischer polyarthritis
WO1997040072A3 (en) Adam proteins and uses thereof
DAHR et al. High Frequency Antigens of Human Erythrocyte Membrane Sialoglycoproteins I. En Receptors in the Glycosylated Domain of the MN Sialoglycoprotein
EE200000478A (et) Peptiid, seda kodeeriv geen, diagnostiline reagent ja diagnostiline reaktiivikomplekt ning vaktsiinkasutamiseks riketsioosi ravis
Ellison et al. Serologic measures in the prevention of periodontal disease
DE69232975D1 (de) Protein p100von menschlichem Herpesvirus Typ 6, die korrespondierenden DNS Squenzen, ihre Herstellung und Verwendung
NO912823D0 (no) Fremgangsmaate for fremstilling av klasse ii-proteinet av neisseria meningitidis samt vaksiner som inneholder dette.
DE59805440D1 (de) Verwendung von lbp zur sepsistherapie
Ino et al. The outer membrane protein I of Pseudomonas aeruginosa PAO1, a possible pollutant of dialysate in hemodialysis, induces cytokines in mouse bone marrow cells
RU94044985A (ru) Способ прогнозирования длительной репарации эрозивно-язвенных дефектов слизистой пилородуоденальной зоны у детей
RU96111557A (ru) Способ лечения нейросенсорной тугоухости
RU94026276A (ru) Рецепторы интерлейкина-12 и антител

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLA, US

Owner name: CHIRON CORP. (N.D.GES.D. STAATES DELAWARE), EM, US

8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLA, US

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS,INC.(N.D.GES, US